Ignite Creation Date:
2024-05-06 @ 3:09 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02213744
Status:
TERMINATED
Last Update Posted:
2017-01-06
First Post:
2014-08-06
Brief Title:
MM-302 Plus Trastuzumab vs Chemotherapy of Physicians Choice Plus Trastuzumab in HER2-Positive Locally AdvancedMetastatic Breast Cancer Patients
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-07
Start Date Type:
None
Primary Completion Date:
2016-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-06
Completion Date Type:
ESTIMATED
First Submit Date:
2014-08-06
First Submit QC Date:
August 7 2014
Study First Post Date:
2014-08-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-01-04
Last Update Post Date:
2017-01-06
Last Update Post Date Type:
ESTIMATED